Baricitinib for the Treatment of Moderate-To-Severe Alopecia Areata

    January 2025 in “ Balkan Medical Journal ”
    Güllü Gencebay, Anıl Gülsel Bahalı, Didem Dizman … Özlem Su
    Studysummary Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 6

    1. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    2. Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata Dermatologic Therapy · 2022
    3. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    4. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    5. A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata Clinical, cosmetic and investigational dermatology · 2021
    6. Treatment of Alopecia Areata: An Australian Expert Consensus Statement Australasian journal of dermatology · 2018

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019